[com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=2000]], com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=2001]]][com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=80632]], camposKey:2193-8245 2023-12-01 In Vivo Confocal Microscopy in Limbal Stem Cell Deficiency After Mesenchymal Stem Cell Transplantation: A Sub-analysis from a Phase I¿II Clinical Trial32513262, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=80421]], camposKey:1757-6512 2023-12-01 Intravitreal allogeneic mesenchymal stem cells: a non-randomized phase II clinical trial for acute non-arteritic optic neuropathy00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=74457]], camposKey:1029-8428 2022-12-01 Advanced Therapy and Clinical Trials to Treat Patients with Optic Nerve Diseases17391757, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75546]], camposKey:2073-4409 2022-08-01 Corneal Regeneration Using Adipose-Derived Mesenchymal Stem Cells00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=88192]], camposKey:0146-0404 2022-01-01 Bone marrow- and adipose tissue-derived mesenchymal stem cells partially restore corneal and limbal epithelial phenotype in a rabbit model of limbal stem cell deficiency00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=76832]], camposKey:1999-4923 2021-01-01 Advanced therapy medicinal products for the eye: definitions and regulatory framework3470, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=76833]], camposKey:1999-4923 2021-01-01 Goals and challenges of stem cell-based therapy for corneal blindness due to limbal deficiency14830, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=76831]], camposKey:1757-6512 2021-01-01 Subconjunctival injection of mesenchymal stem cells for corneal failure due to limbal stem cell deficiency: state of the art00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=66404]], camposKey:1064-3745 2020-01-01 Optimization of Human Limbal Stem Cell Culture by Replating a Single Limbal Explant (Jun, 10.1007/978-1-0716-0599-8_4, 2020)00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41609]], camposKey:1931-5244 2019-01-01 A proof-of-concept clinical trial using mesenchymal stem cells for the treatment of corneal epithelial stem cell deficiency1840, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52915]], camposKey:1699-1036 2019-01-01 Eficacia del trasplante de células madre mesenquimales de médula ósea y de tejido adiposo en un modelo de deficiencia de células madre limbares desarrollado en conejo: estudio comparativo172172, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52916]], camposKey:1699-1036 2019-01-01 Eficacia del trasplante de células madre mesenquimales de médula ósea y de tejido adiposo en un modelo de deficiencia de células madre limbares desarrollado en conejo: estudio comparativo3639, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41608]], camposKey:0927-7765 2019-01-01 Poly-L/DL-lactic acid films functionalized with collagen IV as carrier substrata for corneal epithelial stem cells121129, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52914]], camposKey:1699-1036 2018-01-01 Estudio de la tolerabilidad y la eficacia del trasplante de células madre mesenquimales de médula ósea en un modelo de síndrome de insuficiencia límbica189190, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52913]], camposKey:1699-1036 2017-01-01 Inflamación de la superficie ocular en un modelo parcial y total de síndrome de insuficiencia límbica204204, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=3532]], camposKey:0271-3683 2017-01-01 Successful Consecutive Expansion of Limbal Explants Using a Biosafe Culture Medium under Feeder Layer-Free Conditions685695, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=3528]], camposKey:1066-5099 2017-01-01 Therapeutic Effect of Human Adipose Tissue-Derived Mesenchymal Stem Cells in Experimental Corneal Failure Due to Limbal Stem Cell Niche Damage21602174, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=3540]], camposKey:0014-4835 2016-01-01 Comparison of functional limbal epithelial stem cell isolation methods8394, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=73052]], camposKey:0146-0404 2015-06-01 Comparison of functional limbal epithelial stem cell isolation methods00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49171]], camposKey:0146-0404 2015-01-01 Improvement of limbal and corneal phenotype after transplantation of human adipose tissue-derived mesenchymal stem cells in an in vivo model of ocular surface failure00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49168]], camposKey:0146-0404 2014-01-01 Biosafe culture medium optimization for in vitro expansion of limbal epithelial stem cells for clinical transplantation00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49169]], camposKey:0146-0404 2014-01-01 Safety and preliminary efficacy of human adipose tissue mesenchymal stem cells (hATMSC) to restore the ocular surface in an in vivo experimental model of limbal stem cell deficiency (LSCD)00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=73051]], camposKey:0146-0404 2013-06-01 Chitosan-Gelatin Biopolymers as Carrier Substrata for Limbal Epithelial Stem Cells00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=796]], camposKey:0957-4530 2013-01-01 Chitosan-gelatin biopolymers as carrier substrata for limbal epithelial stem cells28192829, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=755]], camposKey:0271-3683 2013-01-01 Consecutive Expansion of Limbal Epithelial Stem Cells from a Single Limbal Biopsy537549, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=703]], camposKey:1090-0535 2011-01-01 A comparison of stem cell-related gene expression in the progenitor-rich limbal epithelium and the differentiating central corneal epithelium21022117][CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19280]},camposKey: 231 262 Cell Therapy Using Extraocular Mesenchymal Stem Cells 978-3-030-01303-5Corneal Regeneration 1 2019-01-01 Springer][][][][][][][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=63810]]][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=63810]]][com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=996]], com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=997]], com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=998]]][com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=996]], com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=997]], com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=998]]][][][][][][][][][com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@374590f9, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@6064245d, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@7ca0a5c2][][com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63dd73, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63dcc6, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e9ff, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@4d8828, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e944, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63df13, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63df12, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63df11, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e044, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@4d71eb, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@4d71ec][][][][][][][][com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c2341], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c2343], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@4689b1], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@414e9e], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45f841], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@412fcd], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@56f6e1], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@56f6e0], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@56f7c7]][][][][][][com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@16fe3][]
